Trials / Unknown
UnknownNCT03144856
Apatinib as Second Line Therapy in Patients With Advanced Refractory Biliary Tract Cancers
Phase II Study of Apatinib as Second Line Therapy in Patients With Advanced Refractory Biliary Tract Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 39 (estimated)
- Sponsor
- Sun Yat-sen University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to see whether Apatinib is effective in treating patients with advanced refractory biliary tract cancers.
Detailed description
Biliary tract cancers (BTC) includes cholangiocarcinoma and gallbladder carcinoma (GBC). The systematic treatment based on gemcitabine plus cisplatin is recommended as the current standard chemotherapy for unresectable or metastatic BTC. There is no standard recommendation for second line therapy. Apatinib is a tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2(VEGFR-2). This study was conducted to assess the efficacy and safety of Apatinib in patients with advanced refractory BTC who had received first-line chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apatinib | Apatinib 500mg, po, qd, every 4 weeks. |
Timeline
- Start date
- 2017-02-22
- Primary completion
- 2019-03-01
- Completion
- 2019-03-01
- First posted
- 2017-05-09
- Last updated
- 2017-05-09
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03144856. Inclusion in this directory is not an endorsement.